- Home
- IRD vs SOL-USD Comparison
IRD vs SOL-USD Comparison
Compare IRD & SOL-USD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- SOL-USD
- Stock Information
- Founded
- IRD 2018
- SOL-USD N/A
- Country
- IRD United States
- SOL-USD
- Employees
- IRD N/A
- SOL-USD N/A
- Industry
- IRD
- SOL-USD
- Sector
- IRD
- SOL-USD
- Exchange
- IRD NYSE
- SOL-USD
- Market Cap
- IRD 62.0M
- SOL-USD N/A
- IPO Year
- IRD N/A
- SOL-USD N/A
- Fundamental
- Price
- IRD $0.96
- SOL-USD $147.29
- Analyst Decision
- IRD Strong Buy
- SOL-USD
- Analyst Count
- IRD 3
- SOL-USD 0
- Target Price
- IRD $6.33
- SOL-USD N/A
- AVG Volume (30 Days)
- IRD 899.4K
- SOL-USD N/A
- Earning Date
- IRD 08-15-2025
- SOL-USD N/A
- Dividend Yield
- IRD N/A
- SOL-USD N/A
- EPS Growth
- IRD N/A
- SOL-USD N/A
- EPS
- IRD N/A
- SOL-USD N/A
- Revenue
- IRD $13,651,000.00
- SOL-USD N/A
- Revenue This Year
- IRD $51.41
- SOL-USD N/A
- Revenue Next Year
- IRD $68.84
- SOL-USD N/A
- P/E Ratio
- IRD N/A
- SOL-USD N/A
- Revenue Growth
- IRD N/A
- SOL-USD N/A
- 52 Week Low
- IRD $0.65
- SOL-USD N/A
- 52 Week High
- IRD $2.18
- SOL-USD N/A
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- SOL-USD 47.08
- Support Level
- IRD N/A
- SOL-USD $137.79
- Resistance Level
- IRD N/A
- SOL-USD $159.63
- Average True Range (ATR)
- IRD 0.00
- SOL-USD 8.48
- MACD
- IRD 0.00
- SOL-USD 1.45
- Stochastic Oscillator
- IRD 0.00
- SOL-USD 57.60
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.